1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25 | On 11/28/2023 at 10:00AM, Licensing Program Analyst (LPA) G. Luk arrived unannounced to conduct Case Management - Annual Continuation. LPA met with Executive Director, Chelsea Espinoza and explained the purpose of the visit.
During visit, LPA reviewed 5 staff files and staff training. LPA observed staff completed training which includes dementia, food service, resident rights, medication, ADL (Activities of Daily Living) care, and other topics. Last fire drill was conducted on 10/16/2023.
LPA reviewed a sample of resident's medications at around 1:15PM. LPA interviewed 4 residents and 4 staff starting at 3:00PM.
At 12:00PM, LPA observed facility does not have a hospice waiver. Facility currently has 6 residents on hospice care. Facility provided an Approved Hospice Waiver. However, LPA observed the approval letter was for previous facility (015601492) and dated 12/27/2013.
At 1:45PM, LPA observed R3 does not have the following medications at the facility including: Loperamide, Meclizine HCL, Quetiapine Fumarate, Senna, and Lorazepam. LPA observed R3 does not have discontinue orders for the five PRN medications. Additionally, LPA was informed that R3's Culturelle P/F was replaced with Florastor, but facility does not have a discontinue order for Culturelle P/F.
The deficiencies were observed (see LIC 809D) and cited from the California Code of Regulations, Title 22. Failure to correct the deficiencies may result in civil penalties.
Exit interview conducted. A copy of this report and appeal rights were provided. |